Paul M. Harari

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine · 2006 · 5.1K citations · Full text

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

James A. Bonner, Paul M. Harari, J. Giralt et al. · The Lancet Oncology · 2009 · 2K citations

Advanced Head, Neck Cancer, Radiation Therapy +9

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Maura L. Gillison, Andy Trotti, Jonathan Harris et al. · The Lancet · 2018 · 1.2K citations

Radiation Therapy, Medicine, Nasopharyngeal Cancer +8

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

S. Huang, Jonathan M. Bock, Paul M. Harari · PubMed · 1999 · 718 citations

Pathology, Cell Proliferation, Cancer Biology +20

Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.

S. Huang, Paul M. Harari · PubMed · 2000 · 555 citations

Radiation Therapy, Radiation Biology, Medicine +14